Dr. James B. Martel, MD

Dr. Martel practices at Martel Eye Institute in Rancho Cordova, California.

Dr. Martel's NPI, 1851312300, was assigned on July 21, 2006. Dr. Martel graduated from Harvard Medical School in 1981. Dr. Martel holds California license G60544.

Dr. Martel's primary practice is Martel Eye Institute, at 11216 Trinity River Drive, Rancho Cordova, CA 95670. The practice phone is (916) 631-7868.

Dr. Martel's primary practice is Martel Eye Institute in Rancho Cordova, California. Dr. Martel is also affiliated with Dignity Health - Mercy San Juan Medical Center. The medical group on file is San Francisco International Airport (SFO) Medical Clinic. Dmand AI also links Dr. Martel to 2 more hospitals, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Martel practices, 4 sites in all. Vendor and product names are available with a free account.

Ophthalmology is Dr. Martel's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Martel is board certified in ophthalmology by the American Board of Ophthalmology. Dr. Martel is licensed in California.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, conjunctivitis, dry eye, eye infection or inflammation, eyelid inflammation and glaucoma among the conditions Dr. Martel treats.

CMS data shows 2,105 Medicare services from Dr. Martel across 13 procedure codes in 2024, for 531 Medicare patients. Medicare paid $149,876 for them.

CMS counts 531 Medicare patients who saw Dr. Martel in 2024. The largest group is 65 to 74, with 248 patients. 75% of them have high blood pressure, and 70% have high cholesterol. 58% are also on Medicaid. Their average risk score is 1.35, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Martel's median patient age at 54, with 55% women.

In 2024, Dr. Martel wrote 3,150 Medicare Part D claims for 629 patients. 53% of them were for generic drugs. CMS names the drug for 3,040 of them, across 47 drugs with 11 or more claims each, at $681,182 in total drug cost. In 2023, CMS named 2,867 claims across 47 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Martel for performance year 2024, reported individually. Dr. Martel accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Cataract surgery: 1 to 10 procedures (CMS shows small counts as a range)

Melanoma (skin cancer) excision: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 11 papers to Dr. Martel, published from 2013 to 2022. 2021 was the busiest year, with 3. The most frequent topics are Orbital Diseases, Eye Injuries and Plastic Surgery Procedures. Dr. Martel has published most often in Cureus. Dr. Martel's most frequent co-authors are Joseph R. Martel, MD, Liliya Golas, MD and Roy Alfred Semlacher, MD.

Dmand AI links Dr. Martel to 20 clinical trials, 12 of them phase 3 studies. Conditions studied include Conjunctivitis, Bacterial, Dry Eye Syndromes and Eye Infections, Bacterial. Alcon Research sponsors the most, 3.

CMS Open Payments shows 211 general payments to Dr. Martel from 31 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 98% of the total. Alcon Laboratories Inc paid the most, $791.

Dmand AI lists 3 awards for Dr. Martel, most recently Top Doctors in 2021.

Dr. Martel graduated from Harvard Medical School in 1981. Dr. Martel is a member of AAO and ACS.

Dr. Martel is in network with 12 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.